Explore the words cloud of the MicroSPARK project. It provides you a very rough idea of what is the project "MicroSPARK" about.
The following table provides information about the project.
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
|Coordinator Country||United Kingdom [UK]|
|Total cost||212˙933 €|
|EC max contribution||212˙933 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2019-04-01 to 2021-03-31|
Take a look of project's partnership.
|1||THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE||UK (CAMBRIDGE)||coordinator||212˙933.00|
A range of debilitating neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, arise from the formation of amyloidogenic protein aggregates. Molecular chaperones can counteract aggregate formation, but their molecular action mechanisms remain poorly understood. This is chiefly due to the fundamental challenge of resolving heterogeneous and dynamic aggregating protein species in the presence of chaperones. In order to address this challenge and to advance our knowledge of chaperone action, I propose establishing µSPARK, a novel technology that will allow, for the first time, the unravelling of the detailed microscopic mechanisms by which chaperones target and disassemble amyloidogenic protein species in heterogeneous mixtures at the single-molecule level. These new insights will become possible through the first-time combination and seamless integration of two advanced technologies: (i) Miniaturized fluidic sorting devices and (ii) single-molecule fluorescence spectroscopy combined with three-colour coincidence detection. This will enable high-throughput single-particle interrogation of individual chaperone–aggregate complexes providing fundamentally new means for understanding key aspects of chaperone function. To demonstrate the new possibilities, µSPARK will be exploited to unravel the action mechanisms of heat-shock proteins in curtailing amyloid-β peptide and α-synuclein aggregation. This will provide new insights into proteostatic regulatory mechanisms in Alzheimer’s and Parkinson’s disease. The µSPARK technology will then be exploited to dissect—with high throughput and single-particle resolution—the molecular action mechanisms of small-molecule modulators that promote the inhibitory function of chaperones on protein aggregation. This will allow identifying new strategies to ameliorate aggregate toxicity and will pave the way for µSPARK to become a novel screening tool for drug development.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MICROSPARK" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MICROSPARK" are provided by the European Opendata Portal: CORDIS opendata.
The missing pillar. European social policy and Eurosceptic challenges (SOCIALEU)Read More
Deciphering intrarenal communication to unvail mechanisms of chronic kidney diseasesRead More
Understanding the identity of the amniotic fluid stem cellsRead More